We are live on ! Find out more
MBRX icon

Moleculin Biotech
MBRX

13 hedge funds and large institutions have $1.95M invested in Moleculin Biotech in 2017 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 5 increasing their positions, reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

112% more capital invested

Capital invested by funds: $918K → $1.95M (+$1.03M)

0% more ownership

Funds ownership: 0% → 0% (+0%)

13% less funds holding

Funds holding: 15 → 13 (-2)

33% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 6

Holders
13
Holders Change
-2
Holders Change %
-13.33%
% of All Funds
0.32%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
5
Reduced
–
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
VKH
Virtu KCG Holdings
New York
+$124K
2
Vanguard Group
Vanguard Group
Pennsylvania
+$71.8K
3
Geode Capital Management
Geode Capital Management
Massachusetts
+$56.6K
4
TSS
Two Sigma Securities
New York
+$50.1K
5
Truist Financial
Truist Financial
North Carolina
+$47.9K

Top Sellers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
-$117K
2
BlackRock
BlackRock
New York
-$21K
3
Citadel Advisors
Citadel Advisors
Florida
-$20K
4
Goldman Sachs
Goldman Sachs
New York
-$20K
5
TRCT
Tower Research Capital (TRC)
New York
-$4K
Name Holding Trade Value Shares
Change 		Change in
Stake
VKH
1
Virtu KCG Holdings
New York
$676K +$124K +57 +55%
Vanguard Group
2
Vanguard Group
Pennsylvania
$631K +$71.8K +33 +28%
Truist Financial
3
Truist Financial
North Carolina
$168K +$47.9K +22 +122%
TSS
4
Two Sigma Securities
New York
$144K +$50.1K +23 +209%
Geode Capital Management
5
Geode Capital Management
Massachusetts
$110K +$56.6K +26 New
Susquehanna International Group
6
Susquehanna International Group
Pennsylvania
$52K +$26.1K +12 New
Bank of America
7
Bank of America
North Carolina
$47K – – –
UBS Group
8
UBS Group
Switzerland
$26K +$6.53K +3 +100%
Jane Street
9
Jane Street
New York
$22K +$10.9K +5 New
Morgan Stanley
10
Morgan Stanley
New York
$21K – – –
Northern Trust
11
Northern Trust
Illinois
$21K – – –
WS
12
Wedbush Securities
California
$19K – – –
OIA
13
OneDigital Investment Advisors
Kansas
$5K +$2.18K +1 New
AWMS
14
Advocacy Wealth Management Services
Georgia
$2K – – –
NFG
15
Next Financial Group
Texas
$1K – – –
WA
16
WFG Advisors
Texas
$1K – – –
SM
17
Sabby Management
Florida
– -$117K -44 Closed
BlackRock
18
BlackRock
New York
– -$21K -8 Closed
Citadel Advisors
19
Citadel Advisors
Florida
– -$20K -8 Closed
Goldman Sachs
20
Goldman Sachs
New York
– -$20K -8 Closed
AIM
21
Acrospire Investment Management
Illinois
– -$3K -1 Closed
TRCT
22
Tower Research Capital (TRC)
New York
– -$4K -1 Closed

MBRX Hedge Fund Activity: Q2 2017 in Review

13 of the 4,012 institutional investors tracked by Wall St. Rank reported a position in Moleculin Biotech (MBRX) for Q2 2017, worth a combined $1.95M — up 112% from $918K a quarter earlier.

Sellers outnumbered buyers: 6 funds closed out of MBRX and 4 opened new positions — a net loss of 2 holders — while 0 trimmed existing stakes and 5 added.

The largest buyer was Virtu KCG Holdings, adding an estimated $124K. The largest seller was Sabby Management, exiting entirely with an estimated $117K sold.

  • 13 institutional investors held Moleculin Biotech (MBRX) as of Q2 2017, down from 15 in Q1 2017.
  • Funds reported $1.95M of Moleculin Biotech stock for Q2 2017, up 112% quarter-over-quarter.
  • 4 funds opened new Moleculin Biotech positions in Q2 2017 and 6 closed out, a net change of -2 holders.
  • The largest Moleculin Biotech buyer in Q2 2017 was Virtu KCG Holdings, an estimated $124K added.
  • The largest Moleculin Biotech seller in Q2 2017 was Sabby Management, an estimated $117K sold.

Based on aggregated 13F filings for Q2 2017.